Search Results - "Pilie, Patrick Glen"

Replication stress response deficiency (RSRD) and response to immune therapy in clear cell renal cell carcinoma (ccRCC) by Pilie, Patrick Glen, McGrail, Daniel James, Lin, Shiaw-Yih, Jonasch, Eric

“…Abstract only…”
Get full text

Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC) by Hahn, Andrew Warren, Wang, Xuemei, Efstathiou, Eleni, Hwang, Hyunsoo, Zurita, Amado J., Spetsieris, Nicholas, Boukovala, Myrto A, Wang, Jennifer, Araujo, John C., Pilie, Patrick Glen, Siddiqui, Bilal A., Subudhi, Sumit Kumar, Corn, Paul Gettys, Aparicio, Ana, Tu, Shi-Ming, Logothetis, Christopher

“…Abstract only 135 Background: In pre-operative studies, a short duration of AA + LHRHa produced marked cytoreduction in a subset of men with high-risk prostate…”
Get full text

Homologous repair deficiency in VHL -mutated clear cell renal cell carcinoma by Pilie, Patrick Glen, Zhou, Lijun, Peterson, Christine B, Peng, Yang, Peng, Guang, Jonasch, Eric

“…Abstract only 585 Background: Clear cell renal cell carcinoma (ccRCC) displays genomic instability across all tumor stages, indicative of increased replicative…”
Get full text

Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy by Garmezy, Benjamin, Gheeya, Jinesh S., Thein, Kyaw Zin, Pilie, Patrick Glen, Wang, Wanlin, Rodon Ahnert, Jordi, Shaw, Kenna Rael, Meric-Bernstam, Funda, Yap, Timothy A

“…Abstract only 3008 Background: Mutations in DNA polymerase epsilon ( POLE) may induce DNA replication errors, increasing neoantigen load and potentially…”
Get full text

Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial by Viscuse, Paul Vincent, Zhang, Miao, Liu, Jingjing, Tidwell, Rebecca, Subudhi, Sumit Kumar, Zurita, Amado J., Corn, Paul G., Tu, Shi-Ming, Araujo, John C., Wang, Jennifer, Efstathiou, Eleni, Wang, Jianbo, Pilie, Patrick Glen, Troncoso, Patricia, Zhang, Jianhua, Logothetis, Christopher, Aparicio, Ana

“…Abstract only 83 Background: Most prostate cancers are driven by the androgen receptor (AR) and have significant responses to AR inhibition. However,…”
Get full text

Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma (ccRCC) by Pilie, Patrick Glen, Peterson, Christine B, Peng, Yang, Zhou, Lijun, Yap, Timothy Anthony, Peng, Guang, Jonasch, Eric

“…Abstract only…”
Get full text

Real-world outcomes of genetic testing in a GU genetics clinic and evaluation of current guidelines by Pace, Annelise, Woodson, Ashley Henriksen, Slack-Tidwell, Rebecca, Daniels, Molly S., Pilie, Patrick Glen, Litton, Jennifer Keating, Hoskovec, Jennifer M., Jonasch, Eric

“…Abstract only 668 Background: Several known hereditary cancer syndromes confer an increased risk for genitourinary (GU)-related malignancies. Various…”
Get full text

Adiposity and response to androgen signaling inhibition (ASI) in men with metastatic castration-resistant prostate cancer (mCRPC) by Hahn, Andrew Warren, Tidwell, Rebecca, Surasi, Devaki Shilpa, Pilie, Patrick Glen, Frigo, Daniel, Subudhi, Sumit Kumar, Efstathiou, Eleni, Zurita, Amado J., Tu, Shi-Ming, Chapin, Brian Francis, Fogelman, David R., Starbuck, Michael W, Corn, Paul G., Aparicio, Ana, McQuade, Jennifer Leigh, Logothetis, Christopher

“…Abstract only 72 Background: Improved understanding of how host factors influence the efficacy and toxicity of ASI could improve outcomes. Adiposity increases…”
Get full text

Identifying functional loss of ATM gene in patients with advanced cancer by Pilie, Patrick Glen, Gheeya, Jinesh S., Kyewalabye, Keith, Goswamy, Rohit Vivek, Wani, Khalida M, Le, Hung, Campbell, Erick, Sanchez, Nora Sylvia, Yang, Dong, Garmezy, Benjamin, Ileana Dumbrava, Ecaterina Elena, Rodon Ahnert, Jordi, Heffernan, Timothy, Holla, Vijaykumar, Shaw, Kenna Rael, Meric-Bernstam, Funda, Lazar, Alexander J., Wang, Wei-Lien, Yap, Timothy A

“…Abstract only 3629 Background: ATM is frequently mutated in cancer, and defects may serve as a putative predictive biomarker. However, the functional impact of…”
Get full text

Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial by Viscuse, Paul Vincent, Zhang, Miao, Liu, Jingjing, Slack Tidwell, Rebecca, Subudhi, Sumit Kumar, Zurita, Amado J., Corn, Paul Gettys, Tu, Shi-Ming, Araujo, John C., Wang, Jennifer, Efstathiou, Eleni, Wang, Jianbo, Pilie, Patrick Glen, Troncoso, Patricia, Zhang, Jianhua, Logothetis, Christopher, Aparicio, Ana

“…Abstract only 156 Background: AVPC are morphologically heterogeneous tumors that share clinical features with the rare, virulent, androgen-indifferent and…”
Get full text

Genomic instability and DNA damage repair in clear cell renal cell carcinoma by Pilie, Patrick Glen, Zhou, Lijun, Tong, Pan, Matin, Surena F., Sircar, Kanishka, Tamboli, Pheroze, Karam, Jose A., Wood, Christopher G., Hoang, Anh, Jonasch, Eric

“…Abstract only 4581 Background: Kidney cancer accounts for 2-3% of all new cancers with clear cell renal cell carcinoma (ccRCC) the most common subtype. ccRCC…”
Get full text

Pilot study of dovitinib in patients with VHL disease by Pilie, Patrick Glen, Matin, Surena F., Woodson, Ashley Henriksen, Marcott, Valerie D., Bird, Shelly, Slack, Rebecca, Fuller, Greg, McCutcheon, Ian E., Jonasch, Eric

“…Abstract only 587 Background: Von Hippel-Lindau (VHL) is an autosomal dominant inherited disease occurring in 1 in 35,000 births. Individuals with germline…”
Get full text

Evaluation of the aggressive variant prostate cancer molecular profile (AVPCm) in CLIA environments by Viscuse, Paul Vincent, Zhang, Miao, Rohra, Prih, Slack Tidwell, Rebecca, Pritchard, Colin C., Subudhi, Sumit Kumar, Pilié, Patrick Glen, Logothetis, Christopher, Corn, Paul Gettys, Aparicio, Ana

“…250 Background: 20-30% of prostate cancers respond poorly to androgen receptor (AR)-directed therapies and have an atypical, virulent course. The aggressive…”
Get full text

Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC) by Pilié, Patrick Glen, Slack Tidwell, Rebecca, Viscuse, Paul Vincent, Subudhi, Sumit Kumar, Corn, Paul Gettys, Tu, Shi-Ming, Araujo, John C., Zurita, Amado J., Wang, Jennifer, Efstathiou, Eleni, Deinert, Jessica, Logothetis, Christopher, Thompson, Timothy C., Aparicio, Ana

“…196 Background: An aggressive subset of prostate cancers (AVPC) respond poorly to androgen signaling inhibitors, have limited therapeutic options and a dismal…”
Get full text

Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC) by Venkatesh, Neha, Tidwell, Rebecca, Yu, Yao, Aparicio, Ana, Zurita, Amado J., Subudhi, Sumit Kumar, Siddiqui, Bilal Ahmed, Gregg, Justin R., Corn, Paul Gettys, Msaouel, Pavlos, Koutroumpakis, Efstratios, McQuade, Jennifer Leigh, Frigo, Daniel, Pilié, Patrick Glen, Logothetis, Christopher, Huff, Chad, Hahn, Andrew Warren

“…108 Background: ASI is reported to cause adverse changes in body composition, including a loss of muscle mass and increased adiposity and weight. Clinically,…”
Get full text

PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results by Azad, Arun, Voskoboynik, Mark, Joshua, Anthony M., Weickhardt, Andrew James, Sankey, Peter, Pacey, Simon, Heath, Elisabeth I., Krieger, Laurence, Horvath, Lisa, Pilié, Patrick Glen, Womersley, Lynsey, Linardopoulos, Spiros, Moorthy, Ganesh, Zhou, TJ, Brown, Jessica, de Paula, Bruno, Lukacs, Edit, Hudson, Andrew

“…123 Background: The combination of PARP inhibitors (PARPi) with novel hormonal agents (NHAs) has recently demonstrated significant improvement in…”
Get full text

A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio) by Hahn, Andrew Warren, Slack Tidwell, Rebecca, Thoman, Whittney, Abdulla, Amer, Koutroumpakis, Efstratios, Aparicio, Ana, Subudhi, Sumit Kumar, Siddiqui, Bilal Ahmed, Pilié, Patrick Glen, Zurita, Amado J., Corn, Paul Gettys, Laccetti, Andrew Leonard, Jana, Bagi RP, Basen-Engquist, Karen, Logothetis, Christopher

“…TPS273 Background: Prostate cancer is a disease of older age, and there is significant overlap with age-related illnesses. Androgens play a critical role in…”
Get full text

Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss by Dumbrava, Ecaterina Elena, Burton, Elizabeth M., Subudhi, Sumit Kumar, Milton, Denai R., Aparicio, Ana, Yap, Timothy A., Naing, Aung, Corn, Paul Gettys, Pilié, Patrick Glen, Zurita, Amado J., Wang, Jennifer, Amaria, Rodabe Navroze, McQuade, Jennifer Leigh, Glitza, Isabella Claudia, Lazar, Alexander J., Meric-Bernstam, Funda, Logothetis, Christopher, Davies, Michael A., Hwu, Patrick, Tawbi, Hussein A.

“…5052 Background: PTEN loss activates the PI3K/AKT signaling pathway, contributes to an immunosuppressive tumor microenvironment, resistance to androgen…”
Get full text

DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC by Viscuse, Paul Vincent, Tidwell, Rebecca, Liu, Jingjing, Guo, Shuai, Vundavilli, Haswanth, Zhang, Miao, Subudhi, Sumit Kumar, Zurita, Amado J., Corn, Paul Gettys, Tu, Shi-Ming, Araujo, John C., Wang, Jennifer, Efstathiou, Eleni, Wang, Jianbo, Pilié, Patrick Glen, Troncoso, Patricia, Zhang, Jianhua, Wang, Wenyi, Logothetis, Christopher, Aparicio, Ana

“…5059 Background: Response to androgen signaling inhibitors is highly variable and dictates prognosis in castration resistant prostate cancer (CRPC). The…”
Get full text